This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Orthopedic Use of BPC 157 Sports Med Review FDA takes first step in possible reversal of ban on some peptides The Washington Post After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of